Onco Wiki / Indication

Esophageal carcinoma (squamous + adeno) · line 1 · FLOT

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy1
Trackaggressive
Linked regimenREG-FLOT
IDIND-ESOPH-OLIGOMET-SYSTEMIC-PLUS-LOCAL
TypeIndication
Statusreviewed 2026-05-08 | pending_clinical_signoff | actionability review required
DiseasesDIS-ESOPHAGEAL
SourcesSRC-ESMO-ESOPHAGEAL-2024 SRC-NCCN-ESOPHAGEAL-2025 SRC-OMEC-1-KROESE-2023 SRC-RENAISSANCE-AIO-FLOT5

Notes

Esophageal oligometastatic systemic-plus-local track per OMEC-1 consensus + RENAISSANCE / AIO-FLOT5 design extrapolated to esophageal histology. Confidence: moderate (consensus + adenocarcinoma trial extrapolation; NCCN 2B). RENAISSANCE enrolled gastric/GEJ adenocarcinoma — esoph-only + ESCC histologies are extrapolated. Re-grade once full RENAISSANCE primary results published + esoph-specific oligomet RCT data emerge (D2 follow-up). §17 phases: NOT populated for v0.1 (planning doc gi2_wave §4.5 recommendation 2). Local-therapy entities (esophagectomy / metastasectomy Surgery, SBRT RadiationCourse) for oligomet are future Phase C extensions. C2 + C4 chunks will populate Surgery + RadiationCourse for esoph; oligomet phases backfilled when those entities exist. Sequence (induction FLOT → restaging → local therapy → adjuvant FLOT for adenocarcinoma; nivo-chemo for ESCC) described in description / rationale / do_not_do text only. recommended_regimen: REG-FLOT (backfilled 2026-05-08 after C1 PR #435 created REG-FLOT; closes #438). Esoph use is extrapolation from gastric (RENAISSANCE). ESCC histology asymmetry flagged in known_controversies — RENAISSANCE evidence does not directly suppo...

Used By

Algorithms

Red flag